


## AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I\*:



wherein

R<sub>1</sub> is methyl;

R<sub>2</sub> is a residue of formula (c)<sub>1</sub> -Y'-(CH<sub>2</sub>)<sub>n</sub>-(CF<sub>2</sub>)<sub>m</sub>-CH<sub>p</sub>F<sub>q</sub> (c)<sub>1</sub> wherein Y' is a direct bond, O, CO, CHOH or C=NOR<sub>6</sub>, wherein R<sub>6</sub> is H, C<sub>1-4</sub>-alkyl, C<sub>2-4</sub>-alkenyl, C<sub>2-4</sub>-alkynyl or benzyl;


n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2, 3, 4, 5 or 6, provided that the sum of n+m is 3-8;

each of p and q, independently, is 0, 1, 2 or 3, with the proviso that p + q = 3;

and the chain (CH<sub>2</sub>)<sub>n</sub>-(CF<sub>2</sub>)<sub>m</sub>-CH<sub>p</sub>F<sub>q</sub> being optionally interrupted by one carbon-carbon double or triple bond, one CO or one-to-three oxygen atoms;

R<sub>3</sub> is Z-X<sub>2</sub> wherein Z is CH<sub>2</sub>, CHF, CF<sub>2</sub> or CHMe, and X<sub>2</sub> is OH or a residue of formula (a):



wherein Z<sub>1</sub> is a direct bond, CH<sub>2</sub>, CHF, CF<sub>2</sub> or O, and each of R<sub>12</sub> and R<sub>13</sub>, independently, is H or C<sub>1-4</sub>-alkyl, optionally substituted by 1, 2 or 3 halogen

atoms; and each of  $R_4$  and  $R_5$ , independently, is H,  $C_{1-4}$ -alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl in free form or in salt form.

2. (Currently amended) A compound according to Claim 1, wherein  $R_2$  is selected from the group consisting of
  - $Y-C_nF_{2n+1}$ , wherein  $n=3-8$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-CH_2C_nF_{2n+1}$ , wherein  $n=1-7$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-CH_2CH_2C_nF_{2n+1}$ , wherein  $n=1-6$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-CH_2CH_2CH_2C_nF_{2n+1}$ , wherein  $n=1-5$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-(CH_2)_nF$ , wherein  $n=1-7$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-(CH_2)_nCF_3$ , wherein  $n=1-6$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-(CH_2)_nCF_2CH_3$ , wherein  $n=1-4$ , and Y is  $CH_2$ , O or  $C=O$ ;
  - $Y-(CH_2)_n(CF_2)_mCHF_2$ , wherein  $n=0-3$ ,  $m=1-6$ ,  $n+m = 3-7$ , and Y is  $CH_2$ , O or  $C=O$ ; and
  - $Y-(CH_2)_nC(O)CF_3$ , wherein  $n=1-5$ , and Y is  $CH_2$ , O or  $C=O$ .
- 3-7. (Canceled)
8. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof in association with a pharmaceutically-acceptable diluent or carrier therefor.
9. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 1, in free form or in pharmaceutically-acceptable salt form, and at least one co-agent selected from an immunosuppressant agent, an immunomodulatory agent, and an anti-inflammatory agent ~~or~~ and a chemotherapeutic drug.
10. (Currently amended) A method for treating disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-

cell-mediated inflammatory or autoimmune diseases in a subject comprising administering to the subject in need thereof an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof.

11-19. (Canceled)